scholarly journals Recurrence rate of sphenoid wing meningiomas and role of peritumoural brain edema: a single center retrospective study

2021 ◽  
Vol 27 (4) ◽  
pp. 30-37
Author(s):  
Abdalrahman M. Nassar ◽  
Volodymyr I. Smolanka ◽  
Andriy V. Smolanka ◽  
Evelina Z. Murzho ◽  
Dipak Chaulagain
Keyword(s):  
Recurrence Rate ◽  
Tumor Volume ◽  
Tumor Resection ◽  
Tumour Volume ◽  
Low Grade ◽  
Strong Impact ◽  
Pathological Grade ◽  
Simpson Grade ◽  
The Mean

Objective: To evaluate the recurrence rate of the operatively treated sphenoid wing meningiomas (SWMs) in relation to other factors and role of PTBE in recurrence as a prognostic factors in a series of 67 patients. Materials and methods: The magnetic resonance imaging (MRI), and pathology data for 67 patients with SWM, who underwent surgery at Uzhhorod Regional Neurosurgical Center between 2007 and 2021 were examined. The recurrence rate and role of PTBE in recurrence in relation to: gender, age, extend of resection, histopathology, tumor volume, location and time of recurrence were evaluated. Follow-up period ranged from 6 to 168 months (median, 87 months) after surgical resection. Results: In our study, the mean age of patients is 47 years, ranged (20-74), at the average (53.5). Male 16 (23.9%), female 51 (76.1%). Mean tumor volume was (32.8cm3), ranged 4.2cm3-143.7cm3. Edema Index (EI) 1; 27 (40.3%) absent edema, and (EI) >1; in 40 (59.7%) present edema. Recurrence rate was 11 (16.4%) patients, 8 (20.0%) patients with PTBE, as compared to 3 (11.1%) patients without PTBE, (p=0,50). Female (8 patients, 15.7%), male (3 patients, 18.7%). The mean age of recurrence was 50.9 years, ranged (21-75), at the average 52.0 years. The mean age in female was 50.8 years, in male 51.0. Bivariate analysis of simultaneous effect of gender and age on SWM recurrence with logistic regression yield both main effect and interaction effect (β gender=M=7.56±6.44, P=0.24; β age=-0.034±0.031, p=0.28; β interaction term=-0.13±0.12, p=0.26). Out of 11 recurrence cases, (2 cases, 9.5%) with small tumour volume, (5 cases, 15.6%) with medium, (3 cases, 33.3%) with large, and (one case, 20.0%) with giant tumour volume. The effect of tumour volume on recurrence rate is insignificant, χ2=2.42, p=0.49.Location of SWM; the recurrence was in (6 cases, 25.0%) of CM location, (2 cases, 25.0%) of SOM and (3 cases, 11.5%) in lateral SWM, (p=0.19). Pathological grade, in the low grade (Gr.I) 7 recurrence cases (13.0%), as compared to 4cases (44.4%) in atypical Gr II, (p=0.01). Simpson grade, the recurrence rate was; 0% in Gr. I; 13.9% in Gr. II; 20.0% in Gr.III; and 33.3% in Gr. IV and 3 cases had died in the early post op (p<0.05). Conclusion: The factors which had a strong impact on the recurrence rate in our study,; i) pathological grade (Gr. II, atypical type) p=0.01 and ii) Simpson grade (extend of tumor resection, p<0.05), while, PTBE (P=0.50), tumor volume (χ2=2.42, p=0.49) and location (χ2=3.37, p=0.19), are weak and non strong factors for recurrence. However, time of recurrence is shorter in patients with PTBE (W=20.5, p=0.092). WHO Gr. II (Spearman’s p=-0.86, p=0.00063) and negligible for Simpson grade (Spearman’s=-0.15, p=0.66).

Gamma Knife surgery for skull base chordomas and chondrosarcomas

2007 ◽  
Vol 107 (4) ◽  
pp. 752-757 ◽  
Author(s):  
Toshinori Hasegawa ◽  
Dai Ishii ◽  
Yoshihisa Kida ◽  
Masayuki Yoshimoto ◽  
Joji Koike ◽  
...  
Keyword(s):  
Skull Base ◽  
Gamma Knife ◽  
Tumor Volume ◽  
Tumor Resection ◽  
Gamma Knife Surgery ◽  
High Rate ◽  
Tumor Control ◽  
Low Grade ◽  
The Mean ◽  
Skull Base Chordomas

Object The purpose of this study was to evaluate radiosurgical outcomes in skull base chordomas and chondrosarcomas, and to determine which tumors are appropriate for stereotactic radiosurgery as adjuvant therapy following maximum tumor resection. Methods Thirty-seven patients (48 lesions) were treated using Gamma Knife surgery (GKS); 27 had chordomas, seven had chondrosarcomas, and three had radiologically diagnosed chordomas. The mean tumor volume was 20 ml, and the mean maximum and marginal doses were 28 and 14 Gy, respectively. The mean follow-up period was 97 months from diagnosis and 59 months from GKS. Results The actuarial 5- and 10-year survival rates after GKS were 80 and 53%, respectively. The actuarial 5- and 10-year local tumor control (LTC) rates after single or multiple GKS sessions were 76 and 67%, respectively. All patients with low-grade chondrosarcomas achieved good LTC. A tumor volume of less than 20 ml significantly affected the high rate of LTC (p = 0.0182). No patient had adverse radiation effects, other than one in whom facial numbness worsened despite successful tumor control. Conclusions As an adjuvant treatment after resection, GKS is a reasonable option for selected patients harboring skull base chordomas or chondrosarcomas with a residual tumor volume of less than 20 ml. Dose planning with a generous treatment volume to avoid marginal treatment failure should be made at a marginal dose of at least 15 Gy to achieve long-term tumor control.

Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy

2020 ◽  
pp. 1-6
Author(s):  
Marco Raber ◽  
Noor Buchholz ◽  
Augusto Vercesi ◽  
Nashaat A. Hendawi ◽  
Vincenzo Inneo ◽  
...  
Keyword(s):  
Potential Role ◽  
Tumor Volume ◽  
Neoadjuvant Treatment ◽  
Complete Resection ◽  
Bladder Mucosa ◽  
Bladder Tumors ◽  
Muscle Invasive Bladder Cancer ◽  
The Mean ◽  
Muscle Invasive

<b><i>Introduction:</i></b> The endoscopic resection of large and bulky bladder cancers represents a challenge. To reduce the tumor and make it more easy to resect, we used neoadjuvant short and intensive intravesical mitomycin (MMC) therapy. <b><i>Methods:</i></b> Patients with large bladder tumors were evaluated for this study. At cystoscopy, the surgeon evaluated the feasibility of complete resection. In patients where this was not possible, biopsies from the tumor, bladder mucosa, and prostatic urethra were taken. These patients then underwent a short and intensive cytoreductive schedule of intravesical MMC. This was then followed by TUR-BT. <b><i>Results:</i></b> Fifteen patients were included in our study. The mean age was 74 years (range: 56–82; SD ±6 years). Mean tumor size was 51 mm (range: 35–65; SD ±8 mm). After neoadjuvant treatment, complete resection was then feasible in all patients. The mean tumor volume after the chemo-resection had reduced to 34 mm (range: 10–50; SD ±13 mm). No adverse effects were reported. <b><i>Conclusion:</i></b> Intravesical cytoreductive neoadjuvant MMC as an initial treatment of large NMIBC can be considered safe, effective, and feasible.

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

2008 ◽  
Vol 26 (8) ◽  
pp. 1338-1345 ◽  
Author(s):  
Justin S. Smith ◽  
Edward F. Chang ◽  
Kathleen R. Lamborn ◽  
Susan M. Chang ◽  
Michael D. Prados ◽  
...  
Keyword(s):  
Tumor Volume ◽  
Progression Free Survival ◽  
Extent Of Resection ◽  
Malignant Progression ◽  
Low Grade ◽  
Karnofsky Performance Score ◽  
Long Term Outcome ◽  
Free Survival

Purpose The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy. We designed a retrospective study to assess the influence of EOR on long-term outcomes of LGGs. Patients and Methods The study population (N = 216) included adults undergoing initial resection of hemispheric LGG. Region-of-interest analysis was performed to measure tumor volumes based on fluid-attenuated inversion-recovery (FLAIR) imaging. Results Median preoperative and postoperative tumor volumes and EOR were 36.6 cm3 (range, 0.7 to 246.1 cm3), 3.7 cm3 (range, 0 to 197.8 cm3) and 88.0% (range, 5% to 100%), respectively. There was no operative mortality. New postoperative deficits were noted in 36 patients (17%); however, all but four had complete recovery. There were 34 deaths (16%; median follow-up, 4.4 years). Progression and malignant progression were identified in 95 (44%) and 44 (20%) cases, respectively. Patients with at least 90% EOR had 5- and 8-year overall survival (OS) rates of 97% and 91%, respectively, whereas patients with less than 90% EOR had 5- and 8-year OS rates of 76% and 60%, respectively. After adjusting each measure of tumor burden for age, Karnofsky performance score (KPS), tumor location, and tumor subtype, OS was predicted by EOR (hazard ratio [HR] = 0.972; 95% CI, 0.960 to 0.983; P < .001), log preoperative tumor volume (HR = 4.442; 95% CI, 1.601 to 12.320; P = .004), and postoperative tumor volume (HR = 1.010; 95% CI, 1.001 to 1.019; P = .03), progression-free survival was predicted by log preoperative tumor volume (HR = 2.711; 95% CI, 1.590 to 4.623; P ≤ .001) and postoperative tumor volume (HR = 1.007; 95% CI, 1.001 to 1.014; P = .035), and malignant progression-free survival was predicted by EOR (HR = 0.983; 95% CI, 0.972 to 0.995; P = .005) and log preoperative tumor volume (HR = 3.826; 95% CI, 1.632 to 8.969; P = .002). Conclusion Improved outcome among adult patients with hemispheric LGG is predicted by greater EOR.

Morbidity profile following aggressive resection of parietal lobe gliomas

2012 ◽  
Vol 116 (6) ◽  
pp. 1182-1186 ◽  
Author(s):  
Nader Sanai ◽  
Juan Martino ◽  
Mitchel S. Berger
Keyword(s):  
Classification System ◽  
Tumor Volume ◽  
Parietal Lobe ◽  
Tumor Resection ◽  
High Rate ◽  
Low Grade ◽  
High Grade ◽  
Language Pathways ◽  
The Impact ◽  
Glioma Classification

Object The impact of parietal lobe gliomas is typically studied in the context of parietal lobe syndromes. However, critical language pathways traverse the parietal lobe and are susceptible during tumor resection. The authors of this study reviewed their experience with parietal gliomas to characterize the impact of resection and the morbidity associated with language. Methods The study population included adults who had undergone resection of parietal gliomas of all grades. Tumor location was identified according to a proposed classification system for parietal region gliomas. Low- and high-grade tumors were volumetrically analyzed using FLAIR and T1-weighted contrast-enhanced MR imaging. Results One hundred nineteen patients with parietal gliomas were identified—34 with low-grade gliomas and 85 with high-grade gliomas. The median patient age was 45 years, and most patients (53) presented with seizures, whereas only 4 patients had an appreciable parietal lobe syndrome. The median preoperative tumor volume was 31.3 cm3, the median extent of resection was 96%, and the median postoperative tumor volume was 0.9 cm3. Surprisingly, the most common early postoperative neurological deficit was dysphasia (16 patients), not weakness (12 patients), sensory deficits (14 patients), or parietal lobe syndrome (10 patients). A proposed parietal glioma classification system, based on surgical anatomy, was predictive of language deficits. Conclusions This is the largest reported experience with parietal lobe gliomas. The findings suggested that parietal language pathways are compromised at a surprisingly high rate. The proposed parietal glioma classification system is predictive of postoperative morbidity associated with language and can assist with preoperative planning. Taken together, these data emphasize the value of identifying language pathways when operating within the parietal lobe.

scholarly journals Transbasal versus endoscopic endonasal versus combined approaches for olfactory groove meningiomas: importance of approach selection

2018 ◽  
Vol 44 (4) ◽  
pp. E8 ◽  
Author(s):  
James K. Liu ◽  
Nicole A. Silva ◽  
Ilesha A. Sevak ◽  
Jean Anderson Eloy
Keyword(s):  
Surgical Outcomes ◽  
Tumor Volume ◽  
Vascular Involvement ◽  
Total Resection ◽  
Endoscopic Endonasal ◽  
Olfactory Groove ◽  
Significant Difference ◽  
Csf Leakage ◽  
The Mean

OBJECTIVEThere has been much debate regarding the optimal surgical approach for resecting olfactory groove meningiomas (OGMs). In this paper, the authors analyzed the factors involved in approach selection and reviewed the surgical outcomes in a series of OGMs.METHODSA retrospective review of 28 consecutive OGMs from a prospective database was conducted. Each tumor was treated via one of 3 approaches: transbasal approach (n = 15), pure endoscopic endonasal approach (EEA; n = 5), and combined (endoscope-assisted) transbasal-EEA (n = 8).RESULTSThe mean tumor volume was greatest in the transbasal (92.02 cm3) and combined (101.15 cm3) groups. Both groups had significant lateral dural extension over the orbits (transbasal 73.3%, p < 0.001; combined 100%), while the transbasal group had the most cerebral edema (73.3%, p < 0.001) and vascular involvement (66.7%, p < 0.001), and the least presence of a cortical cuff (33.3%, p = 0.019). All tumors in the combined group were recurrent tumors that invaded into the sinonasal cavity. The purely EEA group had the smallest mean tumor volume (33.33 cm3), all with a cortical cuff and no lateral dural extension. Gross-total resection was achieved in 80% of transbasal, 100% of EEA, and 62.5% of combined cases. Near-total resection (> 95%) was achieved in 20% of transbasal and 37.5% of combined cases, all due to tumor adherence to the critical neurovascular structures. The rate of CSF leakage was 0% in the transbasal and combined groups, and there was 1 leak in the EEA group (20%), resulting in an overall CSF leakage rate of 3.6%. Olfaction was preserved in 66.7% in the transbasal group. There was no significant difference in length of stay or 30-day readmission rate between the 3 groups. The mean modified Rankin Scale score was 0.79 after the transbasal approach, 2.0 after EEA, and 2.4 after the combined approach (p = 0.0604). The mean follow-up was 14.5 months (range 1–76 months).CONCLUSIONSThe transbasal approach provided the best clinical outcomes with the lowest rate of complications for large tumors (> 40 mm) and for smaller tumors (< 40 mm) with intact olfaction. The role of EEA appears to be limited to smaller, appropriately selected tumors in which olfaction is already absent. EEA also plays an important adjunctive role when combined with the transbasal approach for recurrent OGMs invading the sinonasal cavity. Careful patient selection using an individualized, tailored strategy is important to optimize surgical outcomes.

Detection of unknown primary neuroendocrine tumors (CUP-NET) using 68Ga DOTA-NOC receptor PET/CT

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4599-4599
Author(s):  
D. Hörsch ◽  
V. Prasad ◽  
V. Ambrosini ◽  
M. Hommann ◽  
S. Fanti ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Primary Tumour ◽  
Unknown Primary ◽  
Low Grade ◽  
Pet Ct ◽  
Pancreatic Net ◽  
The Mean ◽  
Standardised Uptake Values ◽  
F 33

4599 Background: This bi-centric study aimed at determining the role of receptor PET/CT using 68Ga-DOTA-NOC in the detection of undiagnosed primary sites of neuroendocrine tumours (NETs). Methods: Overall 59 patients (M: F 33:26, age 65±9 yr) with documented NET and unknown primary, were enrolled. PET/CT was performed after injection of approximately 100 MBq (46–260 MBq) of 68Ga-DOTA-NOC. The maximum standardised uptake values (SUVmax) were calculated and compared with SUVmax in known pancreatic NET (pNET) and ileum / jejunum / duodenum (SI-NET). The results of PET/CT were also correlated with CT alone. Results: In 35/59 (59%) of patients, 68Ga-DOTA-NOC PET/CT localised the site of the primary: ileum/jejunum (14), pancreas (16), rectum (2), lungs (2) and paraganglioma (1). CT alone (on retrospective analyses) confirmed the findings in 12/59 (20%) patients. The mean SUVmax of identified previously unknown pNET and SI-Net were 18.6 ± 9.8 (range 7.8–34.8) and 9.1± 6.0 (range 4.2–27.8), respectively. SUVmax in patients with previously known pNET and SI-NET were 26.1± 14.5 (range 8.7–42.4) and 11.3±3.7 (range 5.6- 17.9). The SUVmax of the unknown pNET and SI-NET were significantly lower (p< 0.05) as compared to the ones with known primary tumour sites. 19% of the patients had high grade, and 81% low grade NET. In 4/59 patients the primary tumour was subsequently resected (2 pancretic, one ileal and one rectal tumour). Conclusions: Our data indicate that 68Ga- DOTA-NOC PET/CT is highly superior to 111In Octreoscan (17% detection rate for CUP according to literature) and can play a major role in the management of patients with CUP-NET. No significant financial relationships to disclose.

Role of diffusion weighted magnetic resonance imaging in assessment of urinary bladder cancer

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Mahmoud Mohamed S Al Thqaby ◽  
Sherif H Abu-Gamrah ◽  
Ayman M Ibrahem ◽  
Ahmed M Hussein ◽  
Mohamed Elazab
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Pathological Examination ◽  
Low Grade ◽  
Bladder Tumors ◽  
T Stage ◽  
Diffusion Weighted ◽  
Contrast Enhanced ◽  
The Mean

Abstract Purpose The aim of this work is to ellucidate the role of diffusion-weighted imaging in T-stage of bladder cancer, to find correlation between the apparent diffusion coefficient (ADC) and histologic grade and to detect early tumor recurrence. Materials and Methods In this retrospective study, 34 patients were gathered, 28 men and 6 women, with ages ranging from 46 to 90 years, presented with gross hematuria or suspected of urinary bladder tumors detected on U/S and/or CT examinations. The patients were referred to Radiology department at national cancer institute for MRI examination after fulfilling inclusion and exclusion criteria. The urinary bladder tumors were classified in accordance with TNM classification from the American Joint Committee on Cancer into: T1 or lower, T2 (T2a or T2b), T3 (T3a or T3b), and T4.The mean ADC value of patients with low grade tumor (G1) and patients with high grade tumor (G2 or G3) was done The results were compared with histo-pathological examination obtained by transurethral resection (TUR) or after radical cystectomy. Results The overall accuracy of T stage diagnosis was 74.29% for T2-weighted images, 88.57 % for DW images, 80 % for contrast-enhanced images, and about 88.57 % for T2 plus DWIs. The mean ADC of G3 tumors was significantly lower than that of G1 and G2 tumors. Conclusion Our results suggest that adding DWIs to T2WIs lead to marked improvement regarding the accuracy for differentiating T2 or lower tumors from T3 and higher tumors, helping to limit the usage of contrast enhanced MRI imaging as a noninvasive diagnostic tool.

Evaluation of a new concept for the management of skull base chordomas and chondrosarcomas

2005 ◽  
Vol 102 (Special_Supplement) ◽  
pp. 165-170 ◽  
Author(s):  
Guenther Christian Feigl ◽  
Otto Bundschuh ◽  
Alireza Gharabaghi ◽  
Sam Safavi-Abassi ◽  
Amr El Shawarby ◽  
...  
Keyword(s):  
Skull Base ◽  
Tumor Volume ◽  
Tumor Resection ◽  
Volume Reduction ◽  
Recurrence Rates ◽  
Content Type ◽  
The Mean ◽  
Tumor Volume Reduction ◽  
Fine Print

Object. Chordomas and chondrosarcomas of the skull base are rare locally invasive tumors associated with high recurrence rates. The aim of this study was to evaluate the concept of microsurgical tumor volume reduction followed by early gamma knife surgery (GKS). Methods. Thirteen patients with 15 tumors were treated between October 2000 and June 2003. There were three patients (23.1%) with chordomas and 10 (76.9%) with chondrosarcomas. There were nine men and four women who ranged in age between 19 and 69 years. All patients first underwent maximal tumor resection. Within 2 to 10 months after surgery they were treated with GKS. The mean postoperative tumor volume treated with GKS was 9.7 cm3 (range 1.4–20.3 cm3). Follow-up computerized tomography and magnetic resonance imaging examinations with volumetric tumor analysis were performed every 6 months after GKS. The mean treatment dose was 17 Gy and the mean isodose was 52%. The mean follow-up duration was 17 months during which there was only one tumor recurrence at the margin of the radiation field. The mean volume reduction was 35.4%. Conclusions. Results of this treatment strategy are encouraging but the efficacy of this multimodal treatment combining surgery and early GKS requires a longer follow up.

The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study

2021 ◽  
Author(s):  
Tamara Ius ◽  
Sam Ng ◽  
Jacob S Young ◽  
Barbara Tomasino ◽  
Maurizio Polano ◽  
...  
Keyword(s):  
Overall Survival ◽  
Multicenter Study ◽  
Tumor Volume ◽  
High Grade Glioma ◽  
Extent Of Resection ◽  
Early Surgery ◽  
Low Grade ◽  
Surgical Data ◽  
Supratotal Resection

Abstract Background The role of surgery for incidentally discovered diffuse incidental low-grade gliomas (iLGGs) is debatable and poorly documented in current literature. Objective The aim was to identify factors that influence survival for patients that underwent surgical resection of iLGGs in a large multicenter population. Methods Clinical, radiological, and surgical data were retrospectively analyzed in 267 patients operated for iLGG from 4 neurosurgical Centers. Univariate and multivariate analyses were performed to identify predictors of overall survival (OS) and tumor recurrence (TR). Results The OS rate was 92.41%. The 5- and 10-year estimated OS rates were 98.09% and 93.2%, respectively. OS was significantly longer for patients with a lower preoperative tumor volume (P = .001) and higher extent of resection (EOR) (P = .037), regardless the WHO-defined molecular class (P = .2). In the final model, OS was influenced only by the preoperative tumor volume (P = .006), while TR by early surgery (P = .028). A negative association was found between preoperative tumor volumes and EOR (rs = −0.44, P &lt; .001). The median preoperative tumor volume was 15 cm3. The median EOR was 95%. Total or supratotal resection of T2-FLAIR abnormality was achieved in 61.62% of cases. Second surgery was performed in 26.22%. The median time between surgeries was 5.5 years. Histological evolution to high-grade glioma was detected in 22.85% of cases (16/70). Permanent mild deficits were observed in 3.08% of cases. Conclusions This multicenter study confirms the results of previous studies investigating surgical management of iLGGs and thereby strengthens the evidence in favor of early surgery for these lesions.

Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria

2021 ◽  
Vol 42 (1) ◽  
pp. e17-e24 ◽  
Author(s):  
Eli Magen ◽  
Dan-Andrei Waitman ◽  
Natan R. Kahan
Keyword(s):  
High Sensitivity ◽  
Study Groups ◽  
Chronic Spontaneous Urticaria ◽  
Control Group ◽  
Low Grade ◽  
Reactive Protein ◽  
Record Data ◽  
The Mean ◽  
Low Grade Inflammation

Background: Biomarkers of resistance to H1-antihistamines (AH) and omalizumab in chronic spontaneous urticaria (CSU) are still a matter of debate. Objective: To identify clinical and laboratory attributes of the patient that may be predictive of AH and omalizumab resistance in CSU. Methods: We conducted a retrospective observational study by using the electronic patient record data base of patients with CSU and of sex- and age-matched controls. Patients with CSU were divided into three study groups: the CSU group, patients who responded to AHs; the antihistamine-resistant CSU (AH-CSU) group, patients refractory to a fourfold AH dose; and the control group, composed of a random sample of age- and sex-matched subjects, with a case-control ratio of 1:2. The patients in the AH-CSU group treated with omalizumab were compared according to the response or resistance to omalizumab. Results: A total of 106 subjects in the AH-CSU group, 483 in the CSU group, and 1198 in the control group were compared. Both AH-CSU (112.7 ± 43.1 kU/mL) and CSU (129.5 ± 52.4 kU/mL) groups were associated with higher plasma total IgE levels than control group (103.2 ± 49.5 kU/mL; p < 0.001). The AH-CSU group was characterized by a higher plasma high-sensitivity C-reactive protein level (6.4 ± 3.7 mg/L) than the CSU group (4.3 ± 1.4 mg/L; p < 0.001) and the control group (3.1 ± 1.8 mg/L; p < 0.001). The AH-CSU and CSU groups were characterized by a lower mean ± standard deviation basophil counts (0.18 ± 0.16 cells ×109/L and 0.19 ± 0.11 cells ×109/L, respectively) than the control group (0.22 ± 0.09 cells ×109/L; p < 0.001). The mean platelet volume was higher in the AH-CSU group (11.2 ± 0.3 fL) than in the CSU group (11.1 ± 0.4 fL; p = 0.002) and in the control group (10.3 ± 0.4 fL; p < 0.001). There were no significant differences in the mean levels of lymphocytes, monocytes, eosinophils, basophils, and platelets, and the rates of eosinopenia and basopenia between the patients in the AH-CSU group who responded to and those who were resistant to omalizumab. Conclusion: This study provided additional data of interest to examine the pathophysiologic role of low-grade inflammation and basopenia in patients with CSU and resistant to AHs and omalizumab.

Sign in / Sign up

Export Citation Format

Share Document